[New Drug Spotlight] Afuresertib - An oral ATP-competitive pan-AKT inhibitor blocking PI3K/AKT signaling to counter tumor survival and resistance

Afuresertib is an oral, ATP-competitive pan-AKT inhibitor originally from GSK and now developed by Laekna; currently in late-stage trials for solid tumors (e.g., HR+/HER2- breast cancer and mCRPC).

[Commercial Synthesis Spotlight] Development of a Scalable Synthetic Route for Enarodustat

Enarodustat is an orally active hypoxia-inducible factor prolyl hydroxylase (PHD) inhibitor developed by Japan Tobacco for the treatment of renal anemia associated with chronic kidney disease (CKD).

[New Drug Spotlight] Nerandomilast: A First-in-Class Selective PDE4B Inhibitor Targeting Inflammation and Fibrosis in IPF

Nerandomilast is a novel treatment option for adults with idiopathic pulmonary fibrosis (IPF), approved by the U.S. FDA on October 7, 2025.

[Commercial Synthesis Spotlight] Biocatalytic Aerobic Oxidation: A Scalable Route to trans-3-Hydroxy-L-Proline

Trans-3-hydroxy-L-proline is a noncanonical amino acid that plays a vital role in pharmaceutical development.

[New Drug Spotlight] Brensocatib - A First-in-Class DPP1 Inhibitor Targeting Neutrophil-Driven Inflammation in Bronchiectasis

Brensocatib (Brinsupri™) was approved by the U.S. FDA on August 12, 2025, for the treatment of adults and children 12 years of age and older with non-cystic fibrosis bronchiectasis (NCFB).

[Commercial Synthesis Spotlight] Scalable Synthesis of the Key Intermediate of Antibiotic RSC-435830

RSC-435830 (also known as GSK-3342830) is a β-lactam antibiotic featuring a rare C2 (S)-methylcephalosporin motif.

[New Drug Spotlight] Taletrectinib - A Next-Generation ROS1 Inhibitor Targeting Resistant Mutations and Brain Metastases

Taletrectinib (Ibtrozi®; Dovbleron® in China) was approved by China’s NMPA in December 2024 for adult patients with locally advanced or metastatic ROS1-positive NSCLC and received FDA approval on June 11, 2025 for the same indication.

[New Drug Spotlight] Casdatifan - A Second-Generation Oral HIF-2α Inhibitor in Clinical Development for ccRCC

Casdatifan is a second-generation, orally bioavailable HIF-2α inhibitor developed by Arcus Biosciences.